[PDF] - Slide 1 ___________________________________ RTOG Lung Cancer PDF Document

SLIDE 1

Slide 1

RTOG Lung Cancer 2011 Trial Update

RTOG Lung Cancer Committee Chair: Jeffrey Bradley, M.D. Kling Associate Professor Department of Radiation Oncology Washington University School of Medicine

_________________ _ _ _ _ _ ___________________ Slide 2

RTOG Lung Committee

Small Cell Lung Cancer

▫ Limited Stage (Intergroup Trial) ▫ Extensive Stage (RTOG 0937)

Early Stage NSCLC

▫ In-operable (0813 and 0915) ▫ Operable (RTOG 1021/ACOSOG Z4099)

Locally advanced NSCLC

▫ Stage IIIA/B (Intergroup Trial -0617) ▫ Stage IIIA with minimal N2 disease (0839) ▫ Stage IIIA –Individualized RT Rx with PET-adapted boost (1106)

_________________ _ _ _ _ _ ___________________ Slide 3

Monthly RTOG Lung Accrual

_________________ _ _ _ _ _ ___________________

SLIDE 2

Slide 4

Phase III Comparison of Thoracic Radiotherapy Regimens in Limited-stage Small Cell Lung Cancer

CALGB 30610 RTOG 0538

Principal Investigator: Jeff Bogart, MD RTOG PI: Ritsuko Komaki, MD

_________________ _ _ _ _ _ ___________________ Slide 5

CDDP VP-16 CDDP VP-16 CDDP VP-16 CDDP VP-16 70 Gy Gy, 2.0 Gy QD 61.2 Gy, 1.8 Gy QD FB Con bst CDDP VP-16 CDDP VP-16 CDDP VP-16 CDDP VP-16

PCI

45 Gy 1.5 Gy BID CDDP VP-16 CDDP VP-16 CDDP VP-16 CDDP VP-16 R A N D O M I Z E

RTOG 0538 / CALGB 30610

_________________ _ _ _ _ _ ___________________ Slide 6

RTOG 0538/CALGB 30610

Status

▫ Accrual thru 8/11: 185/670 patients  1/3 by RTOG ▫ Interim analysis after initial 30 and 50 patients on each arm showed no difference in toxicity ▫ Accrual continuing to 70 patients per arm for next interim toxicity analysis

_________________ _ _ _ _ _ ___________________

SLIDE 3

Slide 7

Study Design

PCI 20-30 Gy in 5-12 fractions No PCI Random Any response Stratification: Performance score and Institute < 5 weeks 4-6 weeks No response

Chemotherapy (4-6 cycles)

Prophylactic cranial irradiation in extensive disease small cell lung cancer (EORTC 08993-22993)

Slotman et al. NEJM 2007

_________________ _ _ _ _ _ ___________________ Slide 8

(months) 4 8 12 16 20 24 28 32 36 10 20 30 40 50 60 70 80 90 100

PCI Control 1 year: VS. HR: 0.68 (0.52-0.88) p=0.003

Overall survival Prophylactic cranial irradiation in extensive disease small cell lung cancer

13.3% 27.1% Slotman et al. NEJM 2007

_________________ _ _ _ _ _ ___________________ Slide 9

Study Design

PCI 25 Gy in 10 fx IF RT Chest and Other Sites Random Any response

Chemotherapy (4-6 cycles)

Phase II Study of PCI and consolidative Extra-Cranial Radiation for ED-SCLC (RTOG 0937)

Observation PI: Elizabeth Gore, MD Stratify: PR vs CR 1 vs 2-3 mets

_________________ _ _ _ _ _ ___________________

SLIDE 4

Slide 10

RTOG 0937 Specifics

Primary Objective: To compare 1-year median survival
Eligibility:

▫ ES-SCLC, excluding brain metastases AND ▫ Only 1-3 metastatic sites prior to platinum-based chemotherapy AND ▫ Radiographic PR or CR

Sample size = 154
Radiation therapy dosing

▫ PCI given in 2.5 Gy fractions to 25 Gy ▫ Metastases dosing is 3 Gy fractions to 45 Gy ▫ Acceptable alternative is 4 Gy fractions to 40 Gy

_________________ _ _ _ _ _ ___________________ Slide 11

RTOG Lung Committee

Small Cell Lung Cancer

▫ Limited Stage (Intergroup Trial) ▫ Extensive Stage (RTOG 0937)

Early Stage NSCLC

▫ In-operable ▫ Operable (RTOG 1021 / ACOSOG Z4099)

Locally advanced NSCLC

▫ Stage IIIA/B (Intergroup Trial -0617) ▫ Stage IIIA with minimal N2 disease (0839) ▫ Stage IIIA with PET-adapted boost

_________________ _ _ _ _ _ ___________________ Slide 12 Stereotactic Body Radiation Therapy (SBRT)

Pulmonary Vein Bronchus Esophagus Cord Skin Chestwall Lung

Physical Targeting

Early y Stage NSCLC

_________________ _ _ _ _ _ ___________________

SLIDE 5

Slide 13

RTOG 0236 trial for medically inoperable

▫ Very high tumor control (similar to surgery)(94%) ▫ 56% 3-year survival

SBRT has become a standard of care for medically inoperable

patients ▫ Up to 10,000 patients per year in US

RTOG 0236 has become a model for expansion of
ligofractionated ablative radiotherapy

_________________ _ _ _ _ _ ___________________ Slide 14

RTOG 0236: Local Control

36 month local control = 98% (CI: 84-100%) Timmerman et al. : JAMA 2010 1 failure within PTV, 1 within same lobe Local Control (%) 25 50 75 100 Months after Start of SBRT 6 12 18 24 30 36 25 50 75 100 6 12 18 24 30 36 Patients at Risk 55 54 47 46 39 34 23 Fail: 1 Total: 55

/ / / / / / / / / / // / / / / / / / / / / / / / /// / / /

_________________ _ _ _ _ _ ___________________ Slide 15

RTOG: 0236 Disseminated Recurrence

36 month disseminated recurrence = 22% (CI: 12-38%)

6 patients (11%) disseminated within 1 year of Rx

Timmerman et al .JAMA 2010 Disseminated Recurrence (%) 25 50 75 100 Months after Start of SBRT 6 12 18 24 30 36 25 50 75 100 6 12 18 24 30 36 Patients at Risk 55 51 44 43 38 33 21 Fail: 11 Total: 55

/ / / / / / / / / / / / / / / / / / / / / / / /

_________________ _ _ _ _ _ ___________________

SLIDE 6

Slide 16

Overall Survival (%) 25 50 75 100 Months after Start of SBRT 6 12 18 24 30 36 25 50 75 100 6 12 18 24 30 36 Patients at Risk 55 54 47 46 40 35 24 Dead: 26 Total: 55 MST: 48.1 (95% CI): (29.6, not reached)

/ / / / / / /

Overall Survival

36 month

verall survival = 56% (CI: 42-68%)
Median survival is 48.1 months

_________________ _ _ _ _ _ ___________________ Slide 17

0236 Severe Toxicity

No grade 5 toxicities (treatment deaths)
Two (4%) grade 4 protocol specified

toxicity (decline in PFTs to <25% predicted & hypocalcemia)

Seven (13%) grade 3 protocol specified

toxicities

_________________ _ _ _ _ _ ___________________ Slide 18

Treatment Patient Category Local Control 3-year Overall Survival Lobectomy/Pneumonectomy Standard risk

perable

95+% 75-90% Sublobar resection Standard risk

perable

75-95% 61-90% Sublobar resection High risk

perable

75-95% 60-80% Sublobar+brachytherapy High risk

perable

90-95% 65-80% SBRT High risk

perable

90-95%* ?? but likely at least 55% SBRT Medically inoperable 90-95%* 55%

Rough Comparisons

_________________ _ _ _ _ _ ___________________

SLIDE 7

Slide 19

RTOG 0618

Small pilot study in operable patients (N=33)
Primary objective = 2 year local control,

secondary objectives survival and toxicity

Target local control = 90% (similar to lobectomy)

justifying treatment dose

Initial analysis planned for 2012

_________________ _ _ _ _ _ ___________________ Slide 20

Physical Targeting with SBRT

Physical Targeting: Current & Planned Trials

RTOG 0813

Phase I/II study of SBRT for early stage centrally located NSCLC in medically inoperable pts

_________________ _ _ _ _ _ ___________________ Slide 21

0813 - SBRT Dose Levels

Level 5 10 Gy x 5 50 Gy Level 6 10.5 Gy x 5 52.5 Gy Level 7 11 Gy x 5 55 Gy Level 8 11.5 Gy x 5 57.5 Gy Level 9 12 Gy x 5 60 Gy

_________________ _ _ _ _ _ ___________________

SLIDE 8

Slide 22

RTOG 0915-SBRT for early stage medically inoperable lung cancer

12 Gy x 4 R e g i s t e r 34 Gy X 1

Primary Endpoint > grade 3 rates of Toxicity

Respiratory Soft tissue/chest wall Skin

Secondary Endpoints LC/OS/DFS PET response PFTs Biomarkers

R a n d

m

i z e

VS.

PI: Videtic 12 Gy X 4

_________________ _ _ _ _ _ ___________________ Slide 23

Medically Inoperable Early Stage NSCLC

RTOG SBRT Plan

Physical Targeting: Future Plans

Randomize III SBRT 34 Gy X 1 SBRT 12Gy X4 SBRT (18 Gy X 3) Altered Fx SBRT Randomize II RTOG 0915

_________________ _ _ _ _ _ ___________________ Slide 24

ROSEL: Radiosurgery or Surgery for

perable stage I NSCLC

Netherlands Trial PI: Suresh Senan, MD

CLOSED!!! Failed to accrue

_________________ _ _ _ _ _ ___________________

SLIDE 9

Slide 25

Cyberknife Trial (STARS)

Randomized trial comparing surgery

(lobectomy) to SBRT for Stage I NSCLC

SBRT dose: 12.5 Gy x 4 fractions
Cyberknife users only
Multi-institutional
PI: Jack Roth, M.D
Lobectomy candidates

_________________ _ _ _ _ _ ___________________ Slide 26

Histological confirmed Stage I NSCLC High-risk Registration and Randomization ARM 1: Sublobar Resection ± Brachytherapy (SR) ARM 2: Stereotactic Body Radiation Therapy (SBRT) 18 Gy X 3 = 54 Gy F O L L O W U P

ACOSOG Z4099/ RTOG 1021

Hiran C. Fernando, MD (ACOSOG); Robert Timmerman, MD (RTOG)

Activated May 2011

_________________ _ _ _ _ _ ___________________ Slide 27

ACOSOG Z4099/ RTOG 1021

400+ patient randomized trial

▫ Enrolled in 4-5 years (8 patient/month)

Primary endpoint is 3 year overall survival
Randomize prior to treatment

▫ Intent to treat ▫ +/- brachytherapy is optional in surgery arm

CTC Version 4 toxicity assessment for both arms

_________________ _ _ _ _ _ ___________________

SLIDE 10

Slide 28

Realities

Trials in average risk patients have struggled to accrue

▫ Surgeons are uncomfortable ▫ Strategy: high risk operable patients only

Patients struggle with a surgical vs. non-invasive

randomization ▫ Use less ‘radical’ option (sublobar anatomical, wedges) ▫ Can be done through a scope

Now is the time to do this trial!

▫ SBRT momentum for off-protocol therapy will increase

_________________ _ _ _ _ _ ___________________ Slide 29

SBRT Workshops

Held at next few RTOG Semi-annual meetings
Experts:

▫ Timmerman (PI) ▫ Galvin (RTOG medical physics) ▫ Straube and Bosch (ATC) ▫ Dosimitrist

Participants:

▫ Targeted radiation oncologists and physicists

Agenda

▫ How to become credentialed ▫ Plan cases to meet RTOG constraints

Organized by Betty O’Meara at RTOG

_________________ _ _ _ _ _ ___________________ Slide 30

RTOG Lung Cancer Strategy

Small Cell Lung Cancer

▫ Limited Stage ▫ Extensive Stage

Early Stage NSCLC

▫ In-operable ▫ Operable

Locally advanced NSCLC

▫ Stage IIIA/B ▫ Stage IIIA with minimal disease ▫ Stage IIIA with PET-adapted boost

_________________ _ _ _ _ _ ___________________

SLIDE 11

Slide 31

NSCLC IIIA CBDCA AUC =2.0 Paclitaxel 50 mg/m2 XRT 61.2 Gy (1.8 Gy/d) Resectable

Y N

Anatomic lobectomy or

pneumonectomy

Muscle flap for bronchial

stump CBDCA AUC=6 Paclitaxel 225 mg/m2 x 2 cycles

Molecular Targeting with Chemoradiation and Surgery Trimodality Therapy for Stage IIIA Minimal N2 Dz.

RTOG 0229

Pathological mediastinal nodal clearance rate = 63% ASTRO 2010: Mohan et al.

_________________ _ _ _ _ _ ___________________ Slide 32

RTOG 0229: Patient Eligibility

Pathologically proven IIIA or IIIB (N3 excluding SCLV)

NSCLC

Must be considered potential surgical candidate prior to

therapy

Mediastinal LN must be assessed with biopsy proven N2
r N3
Zubrod 0-1
Projected post op FEV 1 at least 800 cc based on FEV 1 =

FEV1 X % perfusion to uninvolved lung from quant V/Q scan

_________________ _ _ _ _ _ ___________________ Slide 33

Tumor Characteristics

(n=57) Histology Squamous Cell Carcinoma 11 (19.3%) Adenocarcinoma 29 (50.9%) Large cell undifferentiated 1 ( 1.8%) NSCLC, NOS 16 (28.1%) AJCC Stage IIIA 56 (98.2%) IIIB 1 ( 1.8%) T-Stage T1 18 (31.6%) T2 28 (49.1%) T3 11 (19.3%) N-Stage N2 56 (98.2%) N3 1 ( 1.8%)

_________________ _ _ _ _ _ ___________________

SLIDE 12

Slide 34

0229 Mediastinal Nodal Clearance

Residual Mediastinal Disease Mediastinal nodal clearance Patients Eligible for Assessment of Primary Endpoint Surgery Performed Reasons for No Surgery Residual Mediastinal Nodes Primary Unresectable Medical contraindications MD refusal Died prior to Surgery Progressive disease Other (N=43*) 16 (37%) 27 (63%) 43 Pts 37 pts 20 pts 6 pts 2 pts 5 pts 1 pt 1 pt 1 pt 4 pts

_________________ _ _ _ _ _ ___________________ Slide 35

RTOG 0229 Survival

Time (Months) Overall Survival % Alive (95% Cl) # at Risk Progression-Free Survival %Alive (95% Cl) # at Risk

6 12 18 24 100% 57 87.7% (76.0, 93.9) 50 77.2% (64.0, 86.1) 43 66.4% (52.5, 77.1) 37 53.8% (40.0, 65.8) 29 100% 57 75.4% (62.1, 84.7) 43 50.8% (37.2, 62.9) 28 38.1% (25.6, 50.5) 21 32.7% (20.9, 45.0) 17 Fail/Total Median (95% Cl) 32/57 26.6 months (18.5, ∞) 45/57 12.9 months (8.0, 18.8)

_________________ _ _ _ _ _ ___________________ Slide 36

Overall Survival by Mediastinal Nodal Clearance Status (RTOG 0229)

Time (Months)

No Mediastinal Nodal Clearance

% Alive (95% Cl) # at Risk

Mediastinal Nodal Clearance

% Alive (95% Cl) # at Risk

6 12 18 24 100 % 16 87.5% (58.6, 96.7) 14 81.3% (52.5, 93.5) 12 60.9% (32.7, 80.3) 9 54.2% (27.1, 75.0) 8 100% 27 100% 27 92.6% (73.5, 98.1) 25 81.5% (61.1, 91.8) 22 66.7% (45.7, 81.1) 17 Fail/Total Median Survival Time (95% Cl) 8/16 32.7 months (13.8, ∞) 12/27 Not Reached

_________________ _ _ _ _ _ ___________________

SLIDE 13

Slide 37

NSCLC IIIA CBDCA AUC =2.0 Paclitaxel 50 mg/m2 XRT 61.2 Gy (1.8 Gy/d) Panitumumab Resectable

Y N

Anatomic lobectomy or

pneumonectomy

Muscle flap for bronchial

stump CBDCA AUC=6 Paclitaxel 225 mg/m2 x 2 cycles Tissue: MALDI-TOF Specimens for proteomic analysis & other correlative studies Resection: MALDI-TOF & other specimens

Molecular Targeting with Trimodality Therapy RTOG 0839

Molecular Targeting: Future Plans

PI: Martin Edelman, MD

_________________ _ _ _ _ _ ___________________ Slide 38

RTOG OG 06 0617 17

A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

_________________ _ _ _ _ _ ___________________ Slide 39

Schema

S T R A T I F Y RT Technique 1.3D-CRT 2.IMRT Zubrod 1.0 2.1 PET Staging 1.No 2.Yes Histology 1.Squamous 2.Non- Squamous R A N D O M I Z E Concurrent Treatment Consolidation Treatment Arm A Concurrent chemotherapy* RT to 60 Gy, 5 x per wk for 6 wks Arm A Consolidation chemotherapy* Arm B Concurrent chemotherapy* RT to 74 Gy, 5 x per wk for 7.5 wks Arm B Consolidation chemotherapy* Arm C Concurrent chemotherapy* and Cetuximab RT to 60 Gy, 5 x per wk for 6 wks Arm C Consolidation chemotherapy* and Cetuximab Arm D Concurrent chemotherapy* and Cetuximab RT to 74 Gy, 5 x per wk for 7.5 wks Arm D Consolidation chemotherapy* and Cetuximab *Carboplatin and paclitaxel

_________________ _ _ _ _ _ ___________________

SLIDE 14

Slide 40

Primary Objective

To compare the overall survival of patients

treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy.

To compare the overall survival of patients

treated with cetuximab versus without cetuximab in the setting of concurrent chemotherapy.

_________________ _ _ _ _ _ ___________________ Slide 41

RTOG 0617

Date opened November 2007 Targeted accrual 500 Projected monthly accrual 9 Total entered through 04/10/11 426 Monthly accrual 10.5 Projected completion November 2011 Monthly accrual (last 6 months) 15.0 Projected completion September 2011

_________________ _ _ _ _ _ ___________________ Slide 42

RTOG 0617

Through 04/10/2011

Projected 324 20% Projected 65 Actual 423

_________________ _ _ _ _ _ ___________________

SLIDE 15

Slide 43

RTOG 0617 Planned Interim Analysis

No difference in toxicity between arms No patient safety concerns

_________________ _ _ _ _ _ ___________________ Slide 44

RTOG 0617 Planned Interim Analysis

Efficacy analysis reveals that we have crossed a futility threshold for the high dose question High-dose radiation (74 Gy) will not result in an

verall survival benefit

The question of whether or not cetuximab confers a survival benefit remains important

_________________ _ _ _ _ _ ___________________ Slide 45

RTOG 0617

Definitely, Probably, or Possibly Related to Treatment (Using CTCAE Version 3.0)

Arm A: 60 Gy Arm B: 74 Gy June 2011 (n=91) Grade (n=82) Grade 1 2 3 4 5 1 2 3 4 5 Worst non-hematologic 12 (13%) 37 (41%) 32 (35%) 7 (8%) 1 (1%) 8 (10%) 30 (37%) 31 (38%) 8 (10%) 1 (1%) Worst overall 3 (3%) 23 (25%) 40 (44%) 22 (24%) 1 (1%) 5 (6%) 23 (28%) 30 (37%) 19 (23%) 1 (1%) Arm A: 60 Gy Arm B: 74 Gy January 2011 (n=71) Grade (n=71) Grade 1 2 3 4 5 1 2 3 4 5 Worst non-hematologic 6 (9%) 29 (41%) 27 (38%) 7 (10%) 1 (1%) 9 (13%) 27 (38%) 24 (34%) 7 (10%) (0%) Worst overall 2 (3%) 19 (27%) 29 (41%) 19 (27%) 1 (1%) 6 (9%) 20 (28%) 26 (37%) 15 (21%) (0%)

_________________ _ _ _ _ _ ___________________

SLIDE 16

Slide 46

RTOG 0617

Definitely, Probably, or Possibly Related to Treatment (Using CTCAE Version 3.0)

Arm C: 60 Gy + Cetuximab Arm D: 74 Gy + Cetuximab June 2011 (n=75) Grade (n=67) Grade 1 2 3 4 5 1 2 3 4 5 Worst non-hematologic 1 (1%) 24 (32%) 38 (51%) 5 (7%) 2 (3%) 1 (2%) 17 (25%) 34 (51%) 5 (8%) 6 (9%) Worst overall 1 (1%) 12 (16%) 38 (51%) 17 (23%) 2 (3%) 1 (2%) 6 (9%) 31 (46%) 19 (28%) 6 (9%) Arm C: 60 Gy + Cetuximab Arm D: 74 Gy + Cetuximab January 2011 (n=57) Grade (n=60) Grade 1 2 3 4 5 1 2 3 4 5 Worst non-hematologic 1 (2%) 19 (33%) 30 (53%) 3 (5%) 2 (4%) 1 (2%) 19 (32%) 27 (45%) 3 (5%) 6 (10%) Worst overall 1 (2%) 11 (19%) 28 (49%) 13 (23%) 2 (4%) 1 (2%) 9 (15%) 28 (47%) 12 (20%) 6 (10%)

_________________ _ _ _ _ _ ___________________ Slide 47

RTOG 0617 Next plans

Two 74 Gy arms are closed to accrual 60 Gy arms +/- Cetuximab are still open to accrual Analysis ongoing

_________________ _ _ _ _ _ ___________________ Slide 48

Thinking newer strategies

Mid-treatment FDG-PET based target

volumes adapted radiation therapy

Isoeffect radiation dose prescriptions
Why?

▫ PET tumor volumes shrink during XRT ▫ May incorporate all Stage III patients, not just those selected to get 74 Gy based on NTCP

_________________ _ _ _ _ _ ___________________

SLIDE 17

Slide 49

RTOG 1106-Multicenter Study

RTOG1106 is going to test the feasibility and efficacy of during-RT PET-MTV based individualized radiation dose escalation in a multicenter setting.

RTOG 0617 high dose arm: Uniform dose prescription

1: Conc. chem- RT 50 Gy/25fx (ED2^=50 Gy) 2: During-RT FDG- PET/CT adaptive chem- RT to MLD 20 Gy $ in 2.4-3.5 Gy/fx for 9-13 fxs to a total of 86 Gy (100 Gy ED2 lung ) /30 fxs R A N D O M I Z E * FDG PET/ CT based RT plan to 74 Gy ED2 Inoperable

r

unresectable Stage III NSCLC (FDG- PET/CT staged) 1: Continue conc. chem-RT to a total of 74 Gy ED2 /37 fxs

r MLD of 20 Gy

2: Concurrent chem-RT to ED2^=50 Gy in 17-21 fxs FDG- PET/CT at 40- 50 Gy ED2^ for all pts

F-Miso-PET for Selected Institutions

Experimental arm: Individualized adaptive RT

_________________ _ _ _ _ _ ___________________ Slide 50

Tumor Volume Reduced During-RT (UMCC 2003-76, UMCC 2006-040)

Change in PET-MTV 40 80 120 160 200 240 280 320 360 400 Pre-RT During-RT Post-RT PET-MTV (cc) Change in CT-GTV 50 100 150 200 250 300 350 400 450 500 Pre-RT During-RT Post-RT CT-GTV (cc) 20 40 60 80 100 120 140 160 180 200 PET-MTV (%) Pre-RT During-RT Post-RT Change in PET-MTV based on Pre-RT Change in CT-GTV based on Pre-RT 25 50 75 100 125 150 175 200 225 250 Pre-RT During-RT Post-RT CT-GTV (%)

_________________ _ _ _ _ _ ___________________ Slide 51

Preliminary Results Arm B

RT Dose >70 Gy NID2 RT Dose <70 Gy NID2

(n=9) (n=9)

Kong. University of Michigan

_________________ _ _ _ _ _ ___________________

SLIDE 18

Slide 52

During-RT PET-CT adapted composite plan: 17.2% lung NTCP~ 86 Gy to during-RT PET-PTV (102 ED2 lung, ~92 Gy ED2 tumor, ~120 Gy BED for a/b=10). Pre-RT PET-CT based plan: 17.2% lung NTCP~ 70 Gy 9.8% NTCP ~ 50 Gy Pre-RT

During-RT

_________________ _ _ _ _ _ ___________________ Slide 53

During-RT PET-CT based plan: 17.2% NTCP- 86 Gy tumor

Pre-RT PET-CT based plan: 17.2% NTCP, 70 Gy tumor

_________________ _ _ _ _ _ ___________________ Slide 54

Pre-RT PET-CT individualized plan: 17.2% NTCP~ 70 Gy to tumor. During-RT PET-CT adapted plan: 17.2% NTCP~ 86 Gy to residual PET-tumor.

B4 tx

_________________ _ _ _ _ _ ___________________

Slide 1

RTOG Lung Cancer 2011 Trial Update

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 2

RTOG Lung Committee

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 3

Monthly RTOG Lung Accrual

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 4

Phase III Comparison of Thoracic Radiotherapy Regimens in Limited-stage Small Cell Lung Cancer

CALGB 30610 RTOG 0538

Principal Investigator: Jeff Bogart, MD RTOG PI: Ritsuko Komaki, MD

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 5

PCI

RTOG 0538 / CALGB 30610

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 6

RTOG 0538/CALGB 30610

▫ Accrual thru 8/11: 185/670 patients  1/3 by RTOG ▫ Interim analysis after initial 30 and 50 patients on each arm showed no difference in toxicity ▫ Accrual continuing to 70 patients per arm for next interim toxicity analysis

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 7

Study Design

Prophylactic cranial irradiation in extensive disease small cell lung cancer (EORTC 08993-22993)

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 8

Overall survival Prophylactic cranial irradiation in extensive disease small cell lung cancer

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 9

Study Design

Phase II Study of PCI and consolidative Extra-Cranial Radiation for ED-SCLC (RTOG 0937)

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 10

RTOG 0937 Specifics

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 11

RTOG Lung Committee

Physical Targeting

Early y Stage NSCLC

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 13

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 14

RTOG 0236: Local Control

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 15

RTOG: 0236 Disseminated Recurrence

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 16

Overall Survival

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 17

0236 Severe Toxicity

toxicity (decline in PFTs to <25% predicted & hypocalcemia)

toxicities

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 18

Rough Comparisons

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 19

RTOG 0618

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 20

Physical Targeting with SBRT

Physical Targeting: Current & Planned Trials

RTOG 0813

Phase I/II study of SBRT for early stage centrally located NSCLC in medically inoperable pts

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 21

0813 - SBRT Dose Levels

Level 5 10 Gy x 5 50 Gy Level 6 10.5 Gy x 5 52.5 Gy Level 7 11 Gy x 5 55 Gy Level 8 11.5 Gy x 5 57.5 Gy Level 9 12 Gy x 5 60 Gy

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 22

RTOG 0915-SBRT for early stage medically inoperable lung cancer

12 Gy x 4 R e g i s t e r 34 Gy X 1

R a n d

i z e

PI: Videtic 12 Gy X 4

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 23

RTOG SBRT Plan

Physical Targeting: Future Plans

Randomize III SBRT 34 Gy X 1 SBRT 12Gy X4 SBRT (18 Gy X 3) Altered Fx SBRT Randomize II RTOG 0915

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 24

ROSEL: Radiosurgery or Surgery for

Netherlands Trial PI: Suresh Senan, MD

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________

Slide 25

Cyberknife Trial (STARS)

(lobectomy) to SBRT for Stage I NSCLC

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 26

ACOSOG Z4099/ RTOG 1021

___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ ___________________________________ Slide 27

_________________ _ _ _ _ _ ___________________ Slide 2

_________________ _ _ _ _ _ ___________________ Slide 3

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 5

_________________ _ _ _ _ _ ___________________ Slide 6

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 8

_________________ _ _ _ _ _ ___________________ Slide 9

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 11

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 14

_________________ _ _ _ _ _ ___________________ Slide 15

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 17

_________________ _ _ _ _ _ ___________________ Slide 18

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 20

_________________ _ _ _ _ _ ___________________ Slide 21

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 23

_________________ _ _ _ _ _ ___________________ Slide 24

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 26

_________________ _ _ _ _ _ ___________________ Slide 27

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 29

_________________ _ _ _ _ _ ___________________ Slide 30

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 32

_________________ _ _ _ _ _ ___________________ Slide 33

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 35

_________________ _ _ _ _ _ ___________________ Slide 36

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 38

_________________ _ _ _ _ _ ___________________ Slide 39

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 41

_________________ _ _ _ _ _ ___________________ Slide 42

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 44

_________________ _ _ _ _ _ ___________________ Slide 45

_________________ _ _ _ _ _ ___________________

_________________ _ _ _ _ _ ___________________ Slide 47

_________________ _ _ _ _ _ ___________________ Slide 48